Medication info

Ibandronate Sodium Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injectionExpired
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
You & Life Sciences Co., Ltd.
Appearance
An injection in a colorless and transparent solution contained in a colorless and transparent glass prefilled syringe with a single-use needle attached.
Packaging
3ml x 1 vial
Approval status
Expired

MFDS item code 202000144 · Notified 2020.01.09

This product's status changed to Expired on 2025.01.09. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled treatment date, administer the injection as soon as possible, then continue regular treatment at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment, defined as serum creatinine of 200 µmol/L(2.3mg/dL) or less or creatinine clearance of 30ml/min or more. Since clinical experience is insufficient in patients with serum creatinine above 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min, use of this medicine is not recommended in these patients. Elderly No dosage adjustment is necessary.
Child administration
Efficacy and safety in children aged 18 years and younger have not been studied.

Ingredients

Manufacturer
You & Life Sciences Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

Used for the treatment of osteoporosis occurring in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled treatment date, administer the injection as soon as possible, then continue regular treatment at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment, defined as serum creatinine of 200 µmol/L(2.3mg/dL) or less or creatinine clearance of 30ml/min or more. Since clinical experience is insufficient in patients with serum creatinine above 200 µmol/L(2.3mg/dL) or creatinine clearance below 30ml/min, use of this medicine is not recommended in these patients. Elderly No dosage adjustment is necessary.

Child administration

Efficacy and safety in children aged 18 years and younger have not been studied.

Precautions

This medication must be administered by intravenous injection, and caution should be exercised since injecting into arteries or around veins may cause tissue damage. Do not use this medication in patients with allergies to this drug or its components, or in patients with untreated hypocalcemia. During treatment, various adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, myalgia, arthralgia, headache, rash, etc. may occur, but most are mild or moderate and do not necessitate discontinuation of treatment. At the initial intravenous injection, influenza-like symptoms such as arthralgia, myalgia, fever, chills, and fatigue may temporarily occur, but usually resolve naturally within a short period. Calcium levels may temporarily decrease during treatment with this medication, so it must be administered after treatment in cases of hypocalcemia or bone and mineral metabolic disorders, and adequate intake of calcium and vitamin D is necessary. Patients undergoing dental treatment or cancer patients may be at risk of osteonecrosis of the jaw, so thorough examination of the oral condition is advisable prior to administration, and excessive dental procedures should be avoided during treatment. This drug may rarely cause osteonecrosis of the bones around the ears, so caution is warranted in patients with chronic ear infections or pain. Severe bone, joint, or muscle pain may occur during osteoporosis treatment, and if such symptoms appear, consultation with medical personnel should be sought immediately. Additionally, atypical fractures of the femur may occur, so if persistent dull pain in the thigh or groin appears, an evaluation by a specialist should be conducted. When administering this drug, immediate treatment and monitoring must be possible to prepare for anaphylaxis or severe allergic reaction. Safety in pregnant or nursing women has not been established, so its use is not recommended. No dose adjustment is necessary for the elderly, but the safety and efficacy in children under 18 years of age have not been confirmed. In the event of overdose, renal and liver functions should be closely monitored, and appropriate treatment should be administered if electrolyte imbalances such as hypocalcemia occur. This drug should not be mixed with calcium-containing solutions or other intravenous medications, and must be diluted with normal saline or 5% dextrose solution before use. After use, do not reuse the syringe and needle, and dispose of them safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral and intertrochanteric fractures, sensory impairment, acute renal failure, dizziness, hypothyroidism, peripheral neuropathy, hearing loss, dyspnea, skin shedding, multiple organ failure, death, optic nerve atrophy, lower motor neuron lesions, tremors, unspecified gastrointestinal diseases, benign gastrointestinal neoplasms, toothache, hyperventilation, cough, laryngitis, vaginitis, menopausal symptoms, insomnia, anxiety, tinnitus, ocular bleeding, heart failure, urinary disorders, hematuria

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent contact with air, and it is recommended to store it at room temperature between 1 and 30 degrees Celsius. This storage condition helps maintain the drug's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

An injection in a colorless and transparent solution contained in a colorless and transparent glass prefilled syringe with a single-use needle attached.

Package unit

3ml x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.